PCR has increasingly replaced toxin A and B enzyme immunoassay (EIA) for the testing of Clostridium difficile infection (CDI). This study evaluated the clinical outcomes of CDI and disease epidemiology since the introduction of PCR. Clinical data and outcomes for patients admitted to a tertiary care centre during 2003 to 2012 were extracted using electronic medical records. Outcomes and incidence of disease were compared between types of CDI testing. In total, 15.6 % of 108 092 patients admitted were tested for CDI. Among patients tested, 6.1 % had positive results. The mean number of tests performed per 1000 admissions by EIA and PCR was 257.4 and 162.6, respectively. A total of 8.2 % of PCR tests were positive compared to 5.0 % of EIA tests (P,0.001). The number of tests performed has decreased and the proportion of positive tests increased since PCR introduction. CDI incidence has remained constant. Only albumin (3.09 vs 3.24 g dl 21 , P 0.002) and inflammatory bowel disease (2.6 vs 7.0 %, P,0.001) status differed between the EIA and PCR groups. While hospital mortality did not differ, patients diagnosed by PCR had a shorter median length of stay (10 vs 8 days, P 0.004). Since PCR testing began, less CDI tests have been performed, but the proportion of positive results has increased. The incidence of CDI has remained constant, suggesting no change in disease epidemiology. The length of stay was shorter in the PCR group, reflective of either earlier detection and quicker onset of therapy or detection of less severe disease. Mortality did not change since the introduction of PCR.
INTRODUCTION
Clostridium difficile is an anaerobic, spore-forming bacillus and a common cause of nosocomial infection, with significant mortality and health-care expense. The burden of hospitalizations related to C. difficile infection (CDI) is high. CDI-related hospitalizations have increased by 23 % annually from 2000 to 2005 (Zilberberg et al., 2008) . In a study of community hospitals from the south-eastern United States, CDI surpassed meticillin-resistant Staphylococcus aureus as the most common cause of nosocomial infection (Miller et al., 2011) . The mortality from nosocomial hospitalized CDI has also an increased over time (Redelings et al., 2007; Zilberberg et al., 2008) . Mortality rates from CDI were 23.7 deaths per million population in 2004 compared to 5.7 deaths per million population in 1999 (Redelings et al., 2007) . Moreover, the costs associated with the management of CDI are substantial, and include costs of management, complications and, importantly, increased duration of hospitalization (Kyne et al., 2002; Ghantoji et al., 2010) .
Toxin A and B enzyme immunoassay (EIA) was broadly used for clinical diagnosis of CDI because of its rapidity in performance, but has largely been replaced by PCR. PCR-based diagnostic tests have increased sensitivity when compared to toxin A and B EIA. Studies have reported that the switch to PCR testing has increased the CDI incidence rates in surveillance data; however, the clinical significance of this increase is unclear (Moehring et al., 2013; Tartof et al., 2014) . The objective of this study was to determine trends over time in the diagnosis of CDI, as well as clinical outcomes, since the introduction of PCR in a single tertiary centre.
METHODS
Study design and population. We conducted a retrospective cohort study, including patients admitted to Beth Israel Deaconess Medical Center (BIDMC), a tertiary care centre in Boston, MA, USA. All patients 18 years or older and admitted during the study period of November 5 2003 to December 20 2012 were included in our cohort. This study was approved by the Committee on Clinical Investigations, the institutional review board at the BIDMC.
Patient characteristics. Electronic medical records were reviewed to extract information on patient demographics, clinical characteristics and time-stamped laboratory test results. Laboratory results from the day of admission, or from first collection, including blood urea nitrogen (BUN), creatinine (Cr), albumin, haemoglobin (Hgb), haematocrit (Hct), sodium (Na) and bicarbonate (HCO 3 ) were extracted. Prior health-care utilization, identified as prior hospitalizations, was extracted. Patient co-morbidities, including diabetes mellitus (DM), human immunodeficiency virus (HIV), hypertension (HTN), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), renal failure, inflammatory bowel disease (IBD) and dementia were identified using the (International Classification of Diseases) ICD 9 codes.
Identification of CDI and clinical outcomes. CDI was identified as a positive CDI result on at least one C. difficile test. At our institution, C. difficile testing is performed only on non-formed stools. Therefore, CDI cases were identified by positive CDI tests on non-formed stools. Prior to 2012, stool specimens were tested by toxins A and B assay using an automated immunoassay (VIDAS C. difficile; bioMérieux). A molecular amplification-based test (illumigene C. difficile; Meridian Bioscience) replaced EIA from January 1 2012.
Death among patients with CDI was determined at any point during their hospital stay. Mean length of hospital stay (date of discharge minus date of inpatient admission) was also determined for patients with CDI confirmed by EIA or PCR.
Statistical analysis. Variable distributions from histogram and quantile-quantile plots were visually inspected to assess for normality. Differences between EIA and PCR were assessed by t-test for normally distributed variables and by non-parametric tests (Mann-Whitney U test) for non-normally distributed variables. Categorical variables were compared using a chi-square test. All statistics were performed using SPSS version 20 (SPSS).
RESULTS
A total of 108 092 patients with at least one inpatient admission from November 5 2003 to December 20 2012 were included in the study cohort ( Fig. 1 ). During this period, a total of 46 830 tests were performed for evaluation of CDI in 16 914 (15.6 %) patients. Among patients tested, 1026 (6.1 %) had a positive C. difficile result. During the period of 2003 to 2011, a total of 43 509 EIA tests were performed, and from January 1 2012 to December 20 2012 3321 PCRs were performed. Among all C. difficile tests performed, 2434 (5.2 %) were positive.
The mean number of tests performed annually with EIA was 5370 and with PCR 3321, which represents a 38.2 % reduction in the mean number of tests performed annually with the introduction of PCR. The mean number of EIA tests performed per 1000 admissions was 257.4 compared to 162.6 for PCR testing. During the study period, 8.2 % of PCR tests performed were positive compared to 5.0 % of EIA tests performed (Pv0.001), which represents a 38.9 % increase in the number of positive tests with PCR. Trends over time indicated that while the number of CDI tests decreased with the use of PCR, the number of positive tests increased (Fig. 2) . The overall incidence of positive C. difficile tests remained fairly constant during this time ( Fig. 3 ).
There was no difference in gender and mean age between patients testing positive for C. difficile with EIA versus PCR (Table 1 ). Patients testing positive by PCR were more likely to report abdominal pain (4.80 compared to 1.16 %, Pv0.001). These patients were also more likely to have a higher mean albumin level (3.24 vs 3.09 g dl 21 , P 0.002) and more likely to have a concomitant diagnosis of IBD (7.0 vs 2.6 %, Pv0.001). The prevalence of IBD patients with CDI hospitalized over the study time frame increased, though the overall absolute prevalence was low (less than 0.1 % of CDI hospitalizations). There was no significant difference in other co-morbidities between the two groups, including: DM, HIV, HTN, CHF, COPD, renal failure and dementia. There was no difference between the two groups in other laboratory parameters, including: BUN, Cr, Hgb, Hct, Na, HCO 3 and prior hospitalization. Patients diagnosed by PCR testing had a shorter median length of stay compared to those diagnosed by EIA (8 vs 10 days, P 0.004). Mortality between the two groups was similar (8.7 % for EIA vs 11.1 % for PCR, P 0.196).
DISCUSSION
CDI is an important enteric disease that is associated with significant morbidity and mortality, and the costs associated with it represent a major burden to the health-care system. The epidemiology of C. difficile is dynamic with the emerging identification of virulent strains and different vulnerable populations, and the advent of testing methods with greater sensitivity. Although the replacement of toxin A and B EIA testing with PCR testing has taken place, very little is known about the performance of PCR testing, or the change in CDI epidemiology and outcomes in a large population-based setting. Our study served to explore these areas. In our patient population, the prevalence of positive C. difficile in patients admitted and tested was 6. (Grein et al., 2014; Tartof et al., 2014) . Previous studies have demonstrated an increase in incidence rates of CDI with PCR (Moehring et al., 2013; Tartof et al., 2014) . However, our study adds to current knowledge by showing that, despite the change in the proportion of positive tests, there was no change in the overall incidence of positive C. difficile compared to prior years.
There was no difference in gender and mean age between patients testing positive for CDI using EIA versus PCR. Patients testing positive by PCR were more likely to report abdominal pain (4.80 compared to 1.16 %, Pv0.001), for unclear reasons. These patients were more likely to have a concomitant diagnosis of IBD (7.0 vs 2.6 %, Pv0.001). Interestingly, patients testing positive for CDI by PCR had slightly higher mean albumin levels (3.24 vs 3.09 g dl 21 , P 0.002). Some studies suggest an increasing finding of community-acquired CDI in young, healthy persons, with little or no health-care contact (Cecil, 2012) . Whether the higher mean albumin in our study is reflective of milder disease severity or a generally healthier subset of patients testing positive by PCR is unclear, particularly since there was no difference in other lab parameters, including white blood cell (WBC) count and BUN, between the EIA-and PCR-positive groups. Moreover, in our study there was no difference in prior health-care utilization between the two groups.
The number of IBD patients diagnosed with CDI increased by nearly threefold with the introduction of PCR testing. This may be secondary to the increased sensitivity of CDI detection in this higher-risk population, increased awareness of the relationship between CDI and IBD, or a true change in the incidence of IBD-related CDI. In our cohort, the prevalence of IBD patients with CDI hospitalized increased slightly over time (up to 0.05 % during the time frame of EIA testing compared to 0.09 % during the time frame of PCR testing). However, the absolute prevalence remained low, with less than 0.1 % of CDI hospitalizations composed of IBD patients. Interestingly, IBD patients with CDI were more likely to report abdominal pain (results not shown). However, it is unlikely that the difference in reported abdominal pain between the EIA and PCR group could only be explained by this small rise in prevalence of IBD patients with CDI. IBD patients with CDI also had lower mean albumin levels compared to the non-IBD patients with CDI. In our study, the mean albumin level was higher in the PCR group. If the small rise in IBD hospitalizations with CDI were to account for the difference in mean albumin, one would expect the mean albumin in the PCR group to be lower not higher compared to the EIA group. There was no significant difference in other co-morbidities between the two groups, including: DM, HIV, HTN, CHF, COPD, renal failure and dementia.
In our study, patients diagnosed by PCR had a shorter length of stay. Patients diagnosed by PCR testing had a median length of stay of 8 days compared to 10 days for patients in the EIA group (P 0.004). As mentioned above, it is possible that severity of illness or overall general health differed between the two groups. However, only mean albumin differed between the two groups, while WBC count, BUN and Cr did not. Moreover, we did not see a difference in co-morbidities except for IBD, which was actually higher in the PCR group. Another explanation for the reduced length of stay in the PCR-positive patients can be related to the increased sensitivity of PCR testing, with earlier detection and possibly quicker onset of treatment. Previous studies have shown a reduction in test frequency, time to positive results and patient isolation times, in addition to unnecessary empiric therapy for C. difficilenegative patients, with the introduction of PCR compared to EIA (Catanzaro & Cirone, 2012; Grein et al., 2014) . Finally, there was no difference in mortality during hospital stay between the two groups.
Costs associated with CDI can vary widely. One study utilizing data from the 2009 Nationwide Inpatient Sample estimated the costs of CDI to be $6774 (£4342) in the USA (Peery et al., 2012) . Other studies have estimated the mean costs of CDI to be between $2454 (£1573) and $4657 (£2985), and as high as $29 000 (£18 590) for hospital-acquired CDI (Kyne et al., 2002; Dubberke et al., 2008; Lipp et al., 2012) . Length of stay is an important factor in the financial burden of CDI (Kyne et al., 2002; Lipp et al., 2012) . Future studies looking at the change in financial burden of CDI with the onset of PCR testing can shed more light on this.
One of the limitations of this study is that patients testing positive for CDI within 48 h of hospitalization were not excluded from analysis. Therefore, we cannot distinguish hospital-acquired CDI from community-acquired CDI. Moreover, while in our hospital CDI testing is performed only in non-formed stool, the increased sensitivity of PCR testing may lend itself to misclassification of CDI cases by picking up colonization as opposed to true infections. A two-step approach (initial specimen screen with either glutamate dehydrogenase EIA or PCR and confirmation with toxin A and B EIA) has been suggested to differentiate between asymptomatic carriers and improve the diagnosis of CDI. This approach is recommended by upcoming European Society of Clinical Microbiology and Infectious Diseases guidelines for the diagnosis of CDI. Finally, our results are limited to a single tertiary centre and may not be applicable in the community setting. However, there are few studies looking at the performance of PCR testing, as well as change in patient-related outcomes since the introduction of PCR in a population-based setting. Also, given our long-term follow up, we were able to capture a large number of admissions and positive C. difficile tests.
In summary, we found that with the introduction of PCR testing, there was no change in the incidence of CDI, but PCR testing resulted in an overall lower number of tests performed and an increased likelihood of positive tests. The mean number of tests performed for CDI detection was reduced by 38.2 %. We also demonstrated an increase in positive results with PCR testing compared to toxin A and B EIA testing by 38.9 %. Patients with CDI detected by PCR were more likely to complain of abdominal pain, have a concomitant diagnosis of IBD, and have a slightly higher mean albumin level. Other co-morbidities and prior hospitalization did not differ between the PCR and EIA groups. While there was no difference in mortality between the two groups, length of stay was reduced in the PCR group, possibly reflective of earlier detection and quicker onset of therapy. Given the financial burden of an increased length of stay due to CDI, this finding is worthy of further investigation. Therefore, PCR testing in our population proved to have a greater power in detection of positive results and was associated with a shorter length of hospital stay when compared to toxin A and B EIA testing.
